Jazz Pharmaceuticals, Inc. (JAZZ) Tops Q2 EPS by 13c, Raises FY Revenue Guidance

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) reported Q2 EPS of $2.05, $0.13 better than the analyst estimate of $1.92. Revenue for the quarter came in at $291.2 million versus the consensus estimate of $273.39 million.

Jazz Pharmaceuticals, Inc. sees FY2014 EPS of $8-$8.25, versus prior guidance of $8-$8.25 and the consensus of $8.07. Jazz Pharmaceuticals, Inc. sees FY2014 revenue of $1.13-1.17 billion, versus prior guidance of $1.10-1.16 billion and the consensus of $1.13 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals, Inc. (JAZZ) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Pfizer reaffirms 2026 guidance after CFO transition news
• UBS Reiterates Buy Rating on Hasbro (HAS) on FY Upside Potential Despite Unchanged Guide